<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150529022468N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-12</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the efficacy and safety of PDL, IPL and long pulse Nd:Yag 1064 laser in the treatment of mild to moderate inflammatory acne vulgaris</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the efficacy and safety of PDL, IPL and Q switch Nd:YAG 1064 laser in the treatment of mild to moderate inflammatory acne vulgaris</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71623</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Over time, patients are randomly divided into three groups. The method of randomization is  *Random allocation rule*. A representative of the first, second and third groups is written and placed inside  envelopes and in order to perform a random sequence (allocation concealment) on the participants, the table of random numbers will be used, Blinding description: A representative of the first, second, and third groups is written and placed inside opaque envelopes (which cannot be seen inside the envelope).
Participant are blinded to the intervention until the end of the study.</study_design>
      <phase>2</phase>
      <hc_freetext>Infammatory facial Acne vulgaris.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Patients in the first group were treated 3 times with an interval of two weeks with PDL laser with a wavelength of 585 nanometers, laser spot diameter of 7 mm, fluence of 3 joules, and pulse duration of 350 microseconds. Intervention 2: Intervention group 2: In the second group, patients are treated 3 times with an interval of two weeks with IPL laser with a wavelength of 240-1200 nanometers and fluence of 7 joules. Intervention 3: Intervention group 3: In the third group, patients are treated 3 times with an interval of two weeks with Nd: Yag long pulse laser with a wavelength of 1064 nanometers and a fluence of 40 joules and a pulse duration of 40 microseconds.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual Data: All potentially shareable data after de-identifying individuals.
Study protocol: The entire protocol can be shared after de-identifying people.
Statistical analysis map: The whole map can be shared after de-identifying people.
Informed Consent Form: Can be shared after de-identifying individuals.
Clinical Study Report: The entire report can be shared after de-identifying individuals.
Codes used in the analysis: All codes can be shared after de-identifying people.
Data classification system: It can be shared after de-identifying people.

When:
The access period starts 6 months after the results are published

To whom:
The data will be available only to researchers working in academic and scientific institutions.

Conditions:
In case of research on a similar topic, he/she can use the data of this study.

Where to obtain:
1- Email: Keramatihaniyeh73@gmail.com
2- Postal address: Rasool Akram Hospital, Mansouri St., Sattar Khan Ave., Tehran

How to obtain:
After correspondence via e-mail or postal address, it is possible to receive data and documents within a period of about two months, if the researcher wishes.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Ghassemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul Akram hospital, Mansouri street, Sattarkhan Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2390</telephone>
        <email>Ghassemi.mr@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammadreza Ghassemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul Akram hospital, Mansouri street, Sattarkhan Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2390</telephone>
        <email>Ghassemi.mr@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Participants over 18 years old with mild to moderate facial inflammatory acne
Not taking isotretinoin in the last 6 months.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of hypertrophic scar or keloid
Anticoagulant drug consumption in the last 2 months
Pregnancy or breastfeeding
Photosensitivity and rheumatologic diseases
Dissatisfaction of patients</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L70.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acne vulgaris</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patients in the first group were treated 3 times with an interval of two weeks with PDL laser with a wavelength of 585 nanometers, laser spot diameter of 7 mm, fluence of 3 joules, and pulse duration of 350 microseconds</i_keyword>
      <i_keyword>Intervention group 2: In the second group, patients are treated 3 times with an interval of two weeks with IPL laser with a wavelength of 240-1200 nanometers and fluence of 7 joules.</i_keyword>
      <i_keyword>Intervention group 3: In the third group, patients are treated 3 times with an interval of two weeks with Nd: Yag long pulse laser with a wavelength of 1064 nanometers and a fluence of 40 joules and a pulse duration of 40 microseconds.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Leeds revised acne grading system. Timepoint: Checking the severity of acne at the beginning of the study and on days 14, 28 and 42 after the intervention. Method of measurement: Based on the number of lesion in the photo and comparing with "Leeds revised acne grading system" a score of 1-12 is given.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Severity of inflammatory facial acne. Timepoint: Measuring the criteria of the global acne grading system at the beginning of the study and on the 14th, 28th, and 42nd days after the start of the study. Method of measurement: Based on the type of lesions, from comedone type to papule, pustule and nodulocystic acne, a score is given from 1 to 44.</sec_outcome>
      <sec_outcome>Quality of life index. Timepoint: Beginning and end of the study (0 and 42th days). Method of measurement: "Dermatology Life Quality Index " questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-18</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran university of medical sciences, Central  headquarters building, Research and technology vice-chancellor, next to Milad tower, Hemmat highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
